Michael Saul Lebowitz - 17 Feb 2026 Form 3 Insider Report for 20/20 Biolabs, Inc.

Role: Chief Scientific Officer
Signature: /s/ Michael Lebowitz
Issuer symbol: N/A
Transactions as of: 17 Feb 2026
Net transactions value: $0
Form type: 3
Filing time: 17 Feb 2026, 18:29:28 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Lebowitz Michael Saul	Chief Scientific Officer	C/O 20/20 BIOLABS, INC., 15810 GAITHER ROAD, SUITE 235, GAITHERSBURG	/s/ Michael Lebowitz	17 Feb 2026	0002109528

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding		Stock Option							17 Feb 2026	Common Stock	50,000	$1.74	Direct	F1
holding		Stock Option							17 Feb 2026	Common Stock	50,000	$2.55	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On January 1, 2023, the Reporting Person was granted a stock option for the purchase of 50,000 shares of common stock, with 25,000 shares vested on the date of the grant and the remaining shares vested in equal monthly installments over the following 24 months.
F2	On July 1, 2024, the Reporting Person was granted a stock option for the purchase of 50,000 shares of common stock, with 12,500 shares vesting on the date of grant and the remaining shares vesting in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service to the Issuer.